Impact of Pharmacist Intervention on Electrocardiogram Monitoring of Pediatric Patients on Multiple QTc Interval–Prolonging Medications

Abstract

OBJECTIVESTo determine whether dedicated pharmacy services improve the rate of electrocardiogram (ECG) monitoring in patients at risk for medication-induced QTc interval prolongation. In addition, determine how pediatric institutions currently monitor patients at risk for medication-induced QTc interval prolongation.METHODS A pharmacist-driven monitoring protocol to detect medication-induced QTc interval prolongation was developed using published literature. If patients were prescribed 3 or more medications known to prolong the QTc interval, they were recommended to have a baseline ECG to assess the QTc interval. If 3 or more QTc interval-prolonging medications were administered for 5 or more days, a follow-up ECG was recommended. Patients prescribed medications known to prolong the QTc interval were identified. Prior to pharmacist intervention, electronic medical records were reviewed to determine if baseline and follow-up ECGs were obtained in patients meeting criteria for monitoring. A dedicated pharmacist then prospectively reviewed charts and recommended monitoring. The rate of monitoring during the intervention and baseline period was compared. To determine current practice at pediatric institutions, a survey was distributed to pharmacists.RESULTS Pharmacist intervention improved the rate of ECG monitoring in patients at risk for medicationinduced QTc interval prolongation from 47.8% to 100% (p = 0.0009). Of the 55 survey participants, 6 stated their institution had QTc interval monitoring procedures in place, 35 did not have any, and 3 had procedures in process.CONCLUSIONS Targeted pharmacist intervention improved the rate of ECG monitoring in patients at risk for medication-induced prolonged QTc interval. Our research and survey data reveal that institutions could benefit from targeted pharmacist intervention to monitor patients for medication-induced QTc interval prolongation.

Evidence demonstrating the pharmacist's direct impact on clinical outcomes in pediatric patients: An opinion of the pediatrics practice and research network of the American College of Clinical Pharmacy

“…The number of patients with a supratherapeutic INR values during admission decreased by over 50% ( P = .039), and goal INR values were documented more consistently in the medical record ( P < .0001). In another free‐standing pediatric hospital, targeted pharmacist inventions to detect patients at risk for medication‐induced QTc interval prolongation were conducted in 88 patients, which were compared against 42 historic controls . The pharmacist recommended baseline ECG in patients receiving three or more medications known to prolong the QTc interval.…”

Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID‐19

“…Yet, low rates of appropriate ECG monitoring have also been identified outside of a pandemic setting. Both Daniel et al 18 and Hutchins et al 19 reported low baseline compliance with QTc monitoring for inpatients receiving QTc‐prolonging drugs at 42% and 47.8%, respectively. Clearly, inadequate QTc monitoring is not a problem unique to this pandemic.…”

Pharmacist Reported Protocols for QTc Monitoring of Psychiatric Medications

“…This barrier could also be an area of future research to determine the pervasiveness and impacts of these concerns. Increasing the scope pharmacists' scope has been shown to reduce QTc interval prolongation and increase appropriate ECG utilization [ 2 , 22 , 23 ]. Another barrier that should be considered is that pharmacists typically work with a supervising prescriber who must approve their therapeutic interventions.…”